Developmental Therapeutics Program

One Dose Mean Graph

NSC: 772642 / 1	Conc: 1.00E-5 Molar	Test Date: Feb 25, 2013
Experiment ID: 1302OS30		Report Date: May 05, 2013

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	80.56
HL-60(TB)	99.83
K-562	99.81
MOLT-4	86.41
RPMI-8226	83.53
SR	90.39
Non-Small Cell Lung Cancer	
A549/ATCC	91.16
HOP-62	105.03
HOP-92	82.00
NCI-H226	91.89
NCI-H23	100.74
NCI-H322M	90.01
NCI-H460	99.53
NCI-H522	81.06
Colon Cancer	
COLO 205	110.36
HCC-2998	103.95
HCT-116	107.14
HCT-15	92.29
HT29	108.15
KM12	101.41
SW-620	107.31
CNS Cancer	
SF-268	98.21
SF-295	100.34
SF-539	98.49
SNB-19	91.37
SNB-75	83.74
U251	91.05
Melanoma	
LOX IMVI	101.91
MALME-3M	105.34
M14	102.60
MDA-MB-435	88.62
SK-MEL-28	99.25
SK-MEL-5	86.93
UACC-257	84.76
UACC-62	82.82
Ovarian Cancer	
IGROV1	112.69
OVCAR-3	97.06
OVCAR-4	100.82
OVCAR-5	103.55
OVCAR-8	97.11
NCI/ADR-RES	105.42
SK-OV-3	101.80
Renal Cancer	
786-0	92.60
A498	76.49
ACHN	90.13
CAKI-1	91.82
RXF 393	92.24
SN12C	94.10
TK-10	97.20
UO-31	71.22
Prostate Cancer	
PC-3	93.07
DU-145	106.26
Breast Cancer	
MCF7	95.64
MDA-MB-231/ATCC	96.88
HS 578T	104.03
BT-549	91.00
T-47D	81.24
MDA-MB-468	86.95
Mean	94.95
Delta	23.73
Range	41.47

Mean Growth Percent - Growth Percent